Jul 24,2017

AgaMatrix and LifeWallet Partner to Facilitate Prevention Care and Remote Monitoring in Populations at Risk of Developing Diabetes

AgaMatrix and LifeWallet announce a collaboration to bring AgaMatrix’s accurate, connected blood glucose monitoring solutions together with LifeWallet’s intuitive apps for health risk assessment and follow up care, for improved outcomes in population health management. LifeWallet is currently piloting this innovative approach to preventative diabetes population health management in collaboration with West Kendall Baptist Hospital, as part of the GE-backed HealthyCities Leadership Academy Open Innovation Challenge. Participants in their Sugar Smart for Life Program undergo a health risk assessment to establish their prediabetes risk. Patients whose levels fell within a pre-diabetic range received wearables and connected devices to capture data such as blood glucose, through AgaMatrix’s Bluetooth® enabled Jazz Wireless 2 Blood Glucose Meter, to understand the impact clinical remote monitoring and engagement may have on reducing blood glucose levels.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Oct 01,2017

AgaMatrix Announces Reorganization, and Formation of WaveForm Technologies Inc.

Upon the reorganization, a new holding company, WaveForm Diabetes (formerly AgaMatrix Holdings, LLC), was formed. WaveForm Diabetes owns 100% of the capital stock of two operating businesses, AgaMatrix, Inc. (“AgaMatrix”), and WaveForm Technologies Inc. (“WaveForm”). The completed financing with Prospect enables WaveForm Diabetes to facilitate capital plans for and investment in both businesses.

View Analyst & Ambassador Comments
Go to original news
Mar 08,2018

WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents

WaveForm Technologies Inc. a developer of novel products for continuous glucose monitoring and a wholly owned subsidiary of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC), announced that the Patent Trial and Appeal Board (PTAB) has ruled two early patents held by WaveForm are not invalid, based on challenges brought by Dexcom, Inc. (NASDAQ: DXCM). WaveForm and AgaMatrix believe that these recent legal victories support the value of its intellectual property and confirm the merits of its Oregon patent suit against Dexcom.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 15,2021

AgaMatrix Europe Awarded Approved Meter Status on the All Wales Formulary

South Oxfordshire, United Kingdom – AgaMatrix Europe Ltd. (“AgaMatrix Europe”), a leading developer of diagnostic technologies for glucose monitoring and wholly-owned subsidiary of AgaMatrix, Inc., announced today that its WaveSense JAZZ™ blood glucose meter (“BGM”) has been approved for use as part of the U.K.’s first national self-monitoring blood glucose formulary. The All Wales formulary is responsible for providing care to more than three million citizens in Wales, including over 200,000 people with diabetes.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Aug 16,2022

Verily’s Onduo, Sword Health collaborate on virtual care

Onduo announced today that it entered into a strategic collaboration with Sword Health to broaden virtual care for diabetes and other conditions. According to a news release, the chronic condition offerings will be provided through Onduo’s solution, while care benefits for MSK pain will also be available through Sword’s platform. The two companies said they aim to provide virtual support solutions to help users adopt healthier lifestyles more easily.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#virtual care

View Analyst & Ambassador Comments
Go to original news
Sep 22,2021

Sweetch Enters Strategic Partnership with Grupo Fleury’s Saúde iD to Tackle Brazil’s Chronic Disease Prevalence

Sweetch, a digital therapeutics innovator and creator of the hyper-personalized engagement platform for chronic conditions, announced a partnership with Grupo Fleury, one of Brazil’s leading healthcare providers. Fleury will implement Sweetch as part of the company’s Saúde iD telemedicine services to improve health care outcomes for patients living with chronic conditions as part of a substantial multi-year contract. Saúde iD is a platform that connects people with doctors and health providers.

COLLABORATION PARTNERSHIP

#product & service

#telehealth

View Analyst & Ambassador Comments
Go to original news
Feb 25,2021

Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly’s connected insulin solutions

Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Under the terms of the agreement, Lilly and Welldoc will collaborate to create a new version of the BlueStar® insulin management solution that integrates insulin dosing data for several Lilly insulins. Lilly will commercialize the pen platform, which will include the new app and Lilly’s connected insulin pen solutions.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#insulin pen

View Analyst & Ambassador Comments
Go to original news

Analyst Note: How To Monetize In The Digital Diabetes Market

Summary

This expert-led presentation on monetization strategies in the digital diabetes market provides insights into the common groups of business models in the market segment. The presentation takes a deep dive into the service offerings from different business models and the competitors’ success stories while offering further potential monetization strategies for digital diabetes companies.

Author: Sue Yoon, Head of Consulting at Research2Guidance

Analyst Note: Global Digital Diabetes Market Size 2022

Summary

This expert-led presentation provides insights on the key aspects of the global digital diabetes market, including the total addressable market size, the top 10 countries by addressable market size, the supply growth from 2012 to 2022, demand changes from 2018 to 2022, and the top 10 most downloaded mobile diabetes applications.

Author: Sue Yoon, Head of Consulting at Research2Guidance

Subscribe to DIABETES